Introduction
Vagococcus fluvialis is a species in the genus
Vagococcus, which is a particular type of Gram-stain positive bacterium that is spherical and similar to
lactococci. It can react with anti-sera against
lactococci [
1]. It was first reported by Collins in 1989 [
2]. To date, this bacterium has been isolated from human clinical specimens in several locations [
3‐
15], including blood, ascites, gallbladder fluid, wound puncture fluid, and root canals. Reports on the pathogenicity of
Vagococcus fluvialis are mostly derived from marine animals such as otters, seals, bass, salmon [
16‐
19], and rainbow trout, as well as infections in domestic animals such as pigs and cows [
20]. This indicates that
Vagococcus fluvialis can infect a variety of animals and can also serve as a source of infection in humans.
Vagococcus fluvialis isolated from urine samples is rarer, and there are no relevant reported cases in China and abroad. There are different symptoms and physical findings depending on the different areas of the body that are affected.
Vagococcus fluvialis infection is not common in humans, and there is limited research on the clinical manifestations and antimicrobial susceptibility testing of Vagococcus fluvialis infection. Here, We isolated Vagococcus fluvialis isolated from the urine samples of bladder cancer patients at Hunan Provincial People’s Hospital. Through initial verification using colony morphology observation on blood agar plates, Gram staining microscopic analysis, and biochemical experiments with an automatic microbiological detection instrument, this pathogenic bacterium is likely to belong to the rare genus of Vagococcus fluvialis. To ensure accurate identification, in conjunction with relevant literature reports, Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) was employed, proving advantageous in identifying rare bacterial species. This study further confirmed the identification of the pathogenic bacterium as riverine roaming cocci through MALDI-TOF MS technology. Meanwhile, we have systematically reviewed other reported Vagococcus infections. It lays an experimental foundation for guiding clinically rational drug use for infections caused by Vagococcus fluvialis and exploring related pathogenic mechanisms.
Materials and methods
Patients and samples
A 60-year-old man presented at Hunan Provincial People’s Hospital with a small amount of blood in his urine, accompanied by urinary frequency, urgency, and pain for over a year. He also had a low-grade fever and blood in his urine constantly for the past 4 days. He did not experience chills, chest tightness, shortness of breath, or difficulty breathing. His mental state, diet, sleep, and bowel movements were normal. Laboratory tests showed that he had a total of 1573.7 red blood cells per microliter, 199.2 white blood cells per microliter, 655.2 bacteria per microliter, a 3 + occult blood in the urine, a 1 + urinary leukocyte esterase, and a 1 + urinary protein. The results suggest that the patient may have a urinary tract infection. Abdominal color Doppler ultrasound showed a solid mass lesion in the anterior and left walls of the bladder. A CTU of the urinary system suggested a bladder mass, with a possibility of malignant tumor originating from the urachus, involving the serosal layer.
Urinary pathogen cultivation and identification
Isolation and cultivation
Urine specimens were collected and inoculated onto Columbia blood agar plates and MacConkey agar plates with alpha-lytic protease inhibitors. The plates were then incubated at 35 °C with 5% CO2 in a incubator-CO2 for 24–48 h, and the colony morphology was observed.
Microscopic examination
Picking a single colony from a blood agar plate of Colombia, preparation of a slide, performing Gram-stain, and microscopic examination using an oil immersion lens.
Strain identification
Picking a pure culture of the test bacterium from a blood agar plate of Colombia, preparing a bacterial suspension of 0.5 McFarland units, based on Gram-stain results, selecting the Gram-stain positive bacteria identification card (GP card) and the Gram-stain positive bacteria susceptibility card (GP67 card) from the VITEK-2 Compact fully automated microbial identification and susceptibility analysis system for testing. The test results are determined using the AES advanced analysis system. Additionally, the test bacterium is streaked onto the target plate of the VITEK MS fully automated rapid microbial mass spectrometry detection system, and 1.0µL CHCA matrix solution is added. After the matrix solution is dried, the sample is analyzed using the machine. Peak comparison and integration calculations are performed using the VITEK MSIVD library, and the identification results are analyzed using the advanced spectrum classifier (ASC) method for high-level mass spectrometry analysis.
Drug sensitivity experiment
Select pure cultures of the test bacteria from Colombia blood agar plates. Prepare a bacterial suspension with a concentration of 0.5 McFarland units. Based on the Gram-stain results, choose the Gram-stain positive bacterial drug sensitivity card, GP67 card, and load it into the VITEK-2 Compact fully automated microbial identification and drug sensitivity analysis system for testing.
Discussion
To date, there have been no reports of culturing
Vagococcus fluvialis from human urine specimens, and there are very few reports of human infections caused by
Vagococcus fluvialis: In 1997, Teixeira [
3] reported the isolation of 4 strains of riverine
Vagococcus fluvialis from human clinical specimens, most of which were initially classified as unidentified enterococci. Teixeira confirmed them as
Vagococcus fluvialis through the study of phenotypic and genotypic characteristics of the isolates, providing the molecular characteristics of
Vagococcus fluvialis and the first evidence of their possible association with human infections. In 2008 [
4], Ali Al-Ahmad isolated
Vagococcus fluvialis from filled teeth with periapical lesions. In 2019 [
9], Jadhav reported a case of
Vagococcus fluvialis infective endocarditis. In 2019 [
11], Zhou reported the isolation of
Vagococcus fluvialis from postoperative infection puncture fluid in the lower segment of the left femur in humans. In 2020 [
12], Kucuk reported a case of
Vagococcus fluvialis isolated from ascites in a patient with liver cirrhosis. In 2023 [
15], Wang first reported the isolation and identification of
Vagococcus fluvialis from gallbladder puncture fluid in patients with chronic cholecystitis.
Vagococcus fluvialis can also be isolated from various injuries in pigs, cows, cats, tonsils, and the tonsils of horses [
20]. It is a Gram-stain positive, catalase-negative cocci. Most of the strains isolated from injury cases were obtained from animals with conditions unrelated to
Vagococcus infections. Only a portion of
Vagococcus fluvialis strains are motile. Many strains produce positive reactions in the V-P test, alkaline phosphatase, and leucine arylamidase test, or ferment lactose and D-tagatose to produce acid. It has been reported that this bacterium causes severe damage to rainbow trout in fish farming at low water temperatures [
21]. Given that
Vagococcus fluvialis can cause infections in both humans and animals, and can be isolated from clinical specimens, it is often misidentified or overlooked in clinical laboratories due to diagnostic challenges. Therefore, when isolating suspected
Vagococcus fluvialis-like bacteria from various specimens, it is important to differentiate them from relevant bacterial species and perform accurate identification. Meanwhile, we also discovered some advanced materials for precise detection of bacteria, as well as the latest nanomedical approaches for treating bacterial infections, which have propelled new strategies for accurate diagnosis and treatment.
We searched for all cases of human infection with
Vagococcus in the PubMed database, Embase database, Google Scholar, China National Knowledge Infrastructure (CNKI), and Wanfang Data. Table
2 shows cases of the previously reported
Vagococcus infections in the Literature in humans.
Table 2
Cases of the previously reported Vagococcus infections in the Literature in humans
| 1997 | N/A | Blood, peritoneal fluid, and wounds | N/A | N/A | Peritonitis, Skin and soft tissue infection | N/A | N/A |
| 2008 | N/A | Root canal | N/A | N/A | Periradicular lesions | N/A | N/A |
| 2009 | N/A | Root canal | N/A | N/A | Periradicular lesions | N/A | N/A |
| 2016 | 58 | Skin wound | Depressive disorder | N/A | Skin and soft tissue infection | Amoxicillin for 15 days | Complete resolution |
| 2016 | 34 | Blood | Intravenous drug abuse | N/A | Infective endocarditis and embolic stroke | Ampicillin and Ceftriaxone for 6 weeks | Complete resolution |
| 2018 | N/A | Blood | N/A | N/A | Infective endocarditis | N/A | N/A |
| 2019 | 70 | Blood from patients with infective endocarditis | Coronary artery bypass graft、Aortic regurgitation | 3 days | Infective endocarditis | Vancomycin was treated for 6 weeks after aortic valve replacement | Complete resolution |
| 2019 | N/A | Foot wound | N/A | N/A | Foot infection | N/A | N/A |
| 2019 | 19 | Infected femoral wound | Left femoral neck fracture、Fracture surgery | 10 months | Postoperative wound infection | Expansion surgery and vancomycin bone cement filling | Partial resolution |
| 2020 | 55 | Ascitic fluid | Liver cirrhosis | N/A | Spontaneous bacterial peritonitis | Antibiotic therapy | N/A |
| 2020 | 74 | Blood from patients with decubitus ulcer infection | Decubitus ulcer | 4 days | Bacteremia | Piperacillin/tazobactam and vancomycin for 4 weeks | Partial resolution |
| 2020 | 78 | Blood | Recurrent urinary tract infections, hysterectomy, hypertension and a cataract operation | 4 days | Skin and soft tissue infection | piperacillin/tazobactam for 12 days | Complete resolution |
| 2023 | 66 | Gallbladder puncture solution | Gastric lymphoma、Post-gastrectomy | N/A | Gallstones with chronic cholecystitis | Cholecystectomy and ceftazidime for a week | Complete resolution |
Although
Vagococcus fluvialis infections are currently extremely rare, these research reports indicate that if timely and appropriate antimicrobial treatment is not given in clinical practice, it can lead to bloodstream infections, and in severe cases, it can be life-threatening. Studies have shown that
Vagococcus fluvialis express a large number of proteins related to known Gram-stain positive bacterial pathogenic and virulence factors, among which enolase and phosphoglycerate kinase are highly expressed, providing further directions for the study of the pathogenic mechanisms of
Vagococcus fluvialis [
1].
Many literature reports indicate that the main pathogens causing urinary tract infections are
Escherichia coli, followed by
Staphylococcus spp.,
Pseudomonas aeruginosa,
Klebsiella spp., and
Proteus spp. However, cases of
Vagococcus fluvialis causing infections are extremely rare. In this study, preliminary verification of the pathogenic bacteria belonging to the rare genus of
Vagococcus fluvialis was conducted through colony morphology observations after blood agar plate cultivation, Gram-stain microscopic analysis, automated microbiological detection instrument bioassays. To ensure accurate identification of the pathogenic bacteria, in combination with relevant literature reports, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was used, which has significant advantages in identifying rare bacterial species [
10,
22]. In this study, MALDI-TOF MS technology was also utilized for identification and the results once again confirmed it to be
Vagococcus fluvialis (with a confidence level of 99.9%).
So far, there is no standard method or criteria for drug sensitivity testing of Vagococcus fluvialis. In this study, the drug sensitivity test of enterococci was used as a reference, which suggests the need for more clinical research to standardize drug sensitivity testing for this bacterium. The patient in this case received cephalosporin treatment for infection upon admission, and based on the patient’s condition and the results of various infection indicators such as blood routine, C-reactive protein, cytokines, and procalcitonin, it was considered that the patient’s infection was still manageable. Postoperative re-examination of urine culture showed no bacterial or fungal growth, and other infection indicators were within normal range. The patient improved and was discharged one week after surgery.
One of the principles of using antimicrobial drugs is that they should not be changed or discontinued arbitrarily. Generally, antimicrobial drugs need to be taken for 2–3 days to reach a certain drug concentration in the body before they take effect. Changing drugs at will is not conducive to the effectiveness of the drugs. The use of antimicrobial drugs should pay attention to the correct drug level. However, not all diseases require high-level drugs. As long as the selected drugs are appropriate, even low-level drugs can exert sufficient effects. Excessive use of high-level drugs can lead to bacterial resistance and affect the efficacy of treatment for severe infections. The selection of appropriate antimicrobial drugs should be based on the characteristics and severity of the infection, and the effects and effectiveness of antimicrobial drugs on pathogenic bacteria are closely related to the characteristics and severity of the disease [
23,
24]. Therefore, this case has certain clinical value for diagnose and the rational use of antimicrobial drugs in patients with
Vagococcus fluvialis infections.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.